drugset
drugset / Trial / NCT00640250

Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response

NCT00640250 ↗

Phase 2 Completed 48 enrolled Allerderm
NaSingle-groupOpen-labelDiagnostic

Summary

We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact dermatitis and a positive patch test (current or previous) to the corresponding reference petrolatum allergen ("sensitives").

Timeline

Start
2008-04
Primary completion
2009-03
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bronopol Small molecule 0.125 unknown Topical
Subject Bronopol Small molecule 0.25 unknown Topical
Subject Bronopol Small molecule 0.5 unknown Topical
Subject Bronopol Small molecule 0.75 unknown Topical
Subject Disperse Blue 106 Unknown 0.017 unknown Topical
Subject Disperse Blue 106 Unknown 0.05 unknown Topical
Subject Disperse Blue 106 Unknown 0.15 unknown Topical

Indications

contact dermatitis